#Japan #Tokyo #ALS #AMED #SOLA Biosciences

SOLA Biosciences Japan's Groundbreaking Initiative

Recently, SOLA Biosciences Japan GK, the Japanese subsidiary of Boston-based SOLA Biosciences Inc., announced a significant development in the treatment of amyotrophic lateral sclerosis (ALS). The company has been granted approximately 6 billion yen (around $55 million) over the next five years by the Japan Agency for Medical Research and Development (AMED). This funding is part of AMED's Strengthening Program for Pharmaceutical Startup Ecosystem, aiming to propel innovative health solutions in the country.

A Focus on ALS

ALS is a devastating neurodegenerative disorder characterized by the progressive degeneration of motor neurons, leading to muscle weakness and, ultimately, paralysis. A central player in the pathology of this disease is the TDP-43 protein, which, in about 97% of ALS cases, becomes misfolded and mislocalized within the neurons. This malfunction contributes significantly to neurodegeneration and the loss of motor function.

The innovative gene therapy developed by SOLA, known as SOL-257, focuses on restoring the normal function of TDP-43. Utilizing the company's proprietary JUMP70 platform technology, SOL-257 seeks to correct the misfolding of TDP-43 while preserving its proper counterparts. The JUMP70 platform combines a disease-specific targeting domain with a protein quality control activation domain to effectively engage HSP70, a crucial molecular chaperone responsible for protein repair and removal.

Collaborative Development

SOLA Japan plans to serve as a key development hub in Japan, closely collaborating with its US-based team, academic institutions, clinical development organizations, and manufacturing partners. By engaging these entities, SOLA aims to leverage a broad spectrum of expertise to enhance the development process of SOL-257.

Curie.Bio, a venture capital firm registered with AMED, is the lead investor in the project, with UTEC (The University of Tokyo Edge Capital Partners) contributing as a follow-on investor. This network of partnerships provides a robust foundation for advancing SOL-257 and emphasizes the integration of scientific and clinical capabilities from both Japan and the United States.

Aiming for First-in-Class Therapy

The ambition behind SOL-257 is to establish it as a first-in-class, disease-modifying gene therapy for ALS. With the support of the AMED grant, the company is on a path towards initiating human clinical trials in both Japan and the United States. Keizo Koya, Ph.D., Founder, CEO, and President of SOLA, expressed deep gratitude for the AMED support, emphasizing the urgency of advancing this initiative efficiently for the benefit of ALS patients and their families. Koya stated, “For ALS patients and their families, time is extremely important. We will continue working closely with researchers, clinicians, investors, manufacturing partners, and pharmaceutical collaborators to bring an innovative new treatment to patients as quickly as possible.”

Yuta Inokuchi, COO of SOLA Japan, underlined the importance of building a coordinated Japan-U.S. development platform, combining Japan's strengths in scientific and clinical landscapes with SOLA's extensive global development capabilities.

Conclusion

SOLA Biosciences Japan's promising journey toward advancing gene therapy for ALS represents a vital response to an unmet medical need. By focusing on the innovative technology behind SOL-257 and fostering international collaborations, SOLA is positioning itself at the forefront of biotechnology and potentially changing the landscape for ALS treatments. As the initiative progresses, it will be exciting to observe the impact on patients suffering from this challenging disease.